Get the Stockscreener App
14.88
1.88%
0.275
Mineralys Therapeutics Inc stock is traded at $14.88, with a volume of 1.05M.
It is up +1.88% in the last 24 hours and up +11.58% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$14.61
Open:
$14.73
24h Volume:
1.05M
Relative Volume:
1.33
Market Cap:
$986.80M
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-5.4524
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
+2.51%
1M Performance:
+11.58%
6M Performance:
+55.70%
1Y Performance:
+32.08%
1-Day Range:
$14.68
$15.46
1-Week Range:
$14.26
$15.55
52-Week Range:
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
14.88 | 1.02B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - MSN
Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade - MSN
Jefferies maintains Hold rating on Mineralys Therapeutics stock ahead of competitor data By Investing.com - Investing.com South Africa
Jefferies maintains Hold rating on Mineralys Therapeutics stock ahead of competitor data - Investing.com Australia
Sector Leaders Rotate Capital Into Mineralys Therapeutics Inc.Portfolio Performance Summary & Accurate Intraday Trade Tips - newsimpact.co.kr
Published on: 2025-08-18 03:13:37 - sundaytimes.kr
Mineralys Therapeutics Advances Hypertension Drug Toward FDA Filing After Strong Clinical Results - MSN
Published on: 2025-08-17 09:08:08 - metal.it
Is Mineralys Therapeutics Inc. likely to announce a buyback2025 Major Catalysts & Consistent Income Trade Recommendations - thegnnews.com
Will Mineralys Therapeutics Inc. announce a stock splitVolume Spike & Accurate Buy Signal Notifications - mustnews.co.kr
Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MSN
Mineralys Therapeutics CMO buys 6,349 shares, sells 11,365 shares in two-day trading period. - AInvest
Mineralys Therapeutics Inc. Enters Reversal Setup in Weekly ChartsWeekly Trend Summary & Free Safe Capital Growth Stock Tips - thegnnews.com
Mineralys Therapeutics shares fall 2.18% intraday after Q2 GAAP loss narrows and insider sells shares. - AInvest
Buy Rating on Mineralys Therapeutics: Promising Outcomes for Lorundrostat in Hypertension and Beyond - TipRanks
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $26 to $45 - 富途牛牛
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q2 2025 Earnings Call Transcript - Insider Monkey
Positive Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Lorundrostat Outcomes and Strong Financial Position - TipRanks
Mineralys signals pre-NDA meeting for lorundrostat in Q4 2025 while expanding clinical programs into cardiorenal comorbidities - MSN
Mineralys Therapeutics Q2 2025: Unraveling Contradictions in Manufacturing, Trials, and Market Strategies - AInvest
Mineralys Therapeutics Reports Positive Q2 2025 Results - TipRanks
Transcript : Mineralys Therapeutics, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Mineralys Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Mineralys Therapeutics beats Q2 2025 EPS forecast, stock rises - Investing.com Australia
Earnings call transcript: Mineralys Therapeutics beats Q2 2025 EPS forecast, stock rises By Investing.com - Investing.com South Africa
Mineralys Therapeutics, Inc. SEC 10-Q Report - TradingView
Mineralys Therapeutics Q2 GAAP Loss Narrows - MarketScreener
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Mineralys' Hypertension Drug Shows Promise in Multiple Studies, Heads Toward FDA Filing - Stock Titan
Technical Bounce Expected in Mineralys Therapeutics Inc. Next WeekMomentum Based Equity Trading Plans Reviewed - beatles.ru
Mineralys Therapeutics Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Mineralys Therapeutics to Announce Q2 Financial Results on August 12 - MSN
Mineralys Therapeutics CFO & Secretary Adam Levy Sells 36% Of Holding - simplywall.st
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 - The Manila Times
Momentum Screeners Rank Mineralys Therapeutics Inc. in Top 5 TodaySwing Trading Plan With Smart Signals in Review - beatles.ru
Support Zone Holds Steady for Mineralys Therapeutics Inc. After DipLow Capital High Return Stock Plans Reviewed - metal.it
Mineralys Therapeutics to Announce Second Quarter 2025 - GlobeNewswire
What drives Mineralys Therapeutics Inc. stock priceAchieve consistent profits with smart trading - Jammu Links News
How many analysts rate Mineralys Therapeutics Inc. as a “Buy”Explosive trading growth - Jammu Links News
What are Mineralys Therapeutics Inc. company’s key revenue driversBuild a diversified portfolio for risk management - Jammu Links News
What catalysts could drive Mineralys Therapeutics Inc. stock higher in 2025Unlock exclusive trading tools and resources - Jammu Links News
Mineralys Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough investment performance - Jammu Links News
Is Mineralys Therapeutics Inc. stock overvalued or undervaluedBuild wealth steadily with smart stock selection - Jammu Links News
What is the dividend policy of Mineralys Therapeutics Inc. stockCapitalize on market trends with confidence - jammulinksnews.com
How volatile is Mineralys Therapeutics Inc. stock compared to the marketMaster the art of timing market moves - Jammu Links News
How strong is Mineralys Therapeutics Inc. company’s balance sheetCapitalize on fast-moving trading opportunities - Jammu Links News
Is it the right time to buy Mineralys Therapeutics Inc. stockBuild a balanced portfolio for long-term success - Jammu Links News
CFO & Secretary Of Mineralys Therapeutics Sold 36% Of Their Shares - 富途牛牛
Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and Development of Newer Therapies During the Study Period (2020-2034) | DelveInsight - Yahoo Finance
Mineralys Therapeutics Insider Sold Shares Worth $1,077,477, According to a Recent SEC Filing - 富途牛牛
Mineralys Therapeutics CFO Adam Levy sells $1m+ in shares By Investing.com - Investing.com Australia
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mineralys Therapeutics Inc Stock (MLYS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer |
Aug 13 '25 |
Sale |
12.93 |
11,365 |
146,987 |
92,891 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):